BR112019018950A2 - métodos para tratamento de doenças e distúrbios mediados por complemento - Google Patents
métodos para tratamento de doenças e distúrbios mediados por complemento Download PDFInfo
- Publication number
- BR112019018950A2 BR112019018950A2 BR112019018950-5A BR112019018950A BR112019018950A2 BR 112019018950 A2 BR112019018950 A2 BR 112019018950A2 BR 112019018950 A BR112019018950 A BR 112019018950A BR 112019018950 A2 BR112019018950 A2 BR 112019018950A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471190P | 2017-03-14 | 2017-03-14 | |
| US62/471,190 | 2017-03-14 | ||
| US201762553059P | 2017-08-31 | 2017-08-31 | |
| US62/553,059 | 2017-08-31 | ||
| PCT/US2018/022462 WO2018170145A1 (en) | 2017-03-14 | 2018-03-14 | Methods for treating complement-mediated diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019018950A2 true BR112019018950A2 (pt) | 2020-04-22 |
Family
ID=61873979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019018950-5A BR112019018950A2 (pt) | 2017-03-14 | 2018-03-14 | métodos para tratamento de doenças e distúrbios mediados por complemento |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210115116A1 (https=) |
| EP (1) | EP3596121A1 (https=) |
| JP (3) | JP7293122B2 (https=) |
| KR (2) | KR20260039796A (https=) |
| CN (1) | CN110753701A (https=) |
| AU (2) | AU2018236267B2 (https=) |
| BR (1) | BR112019018950A2 (https=) |
| CA (1) | CA3055781A1 (https=) |
| CR (1) | CR20190468A (https=) |
| IL (2) | IL325084A (https=) |
| MX (2) | MX2019010994A (https=) |
| SG (1) | SG11201907583TA (https=) |
| TW (2) | TW202513092A (https=) |
| WO (1) | WO2018170145A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2016164358A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| HUE073475T2 (hu) | 2016-10-12 | 2026-01-28 | Bioverativ Usa Inc | C1s elleni antitestek és alkalmazási eljárásaik |
| WO2020121282A1 (en) | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| WO2021108447A1 (en) * | 2019-11-26 | 2021-06-03 | Omeros Corporation | Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant |
| FI129383B (en) * | 2020-06-15 | 2022-01-31 | Faron Pharmaceuticals Oy | Stable anti-clever-1 antibody formulation |
| IL300376A (en) | 2020-08-06 | 2023-04-01 | Bioverativ Usa Inc | Inflammatory cytokines and fatigue in subjects with complement-mediated disease |
| CN117241828A (zh) | 2021-03-31 | 2023-12-15 | 美国比奥维拉迪维股份有限公司 | 减少冷凝集素病患者的手术相关溶血 |
| CN117769434A (zh) | 2021-05-20 | 2024-03-26 | 黛安瑟斯医疗运营公司 | 与C1s结合的抗体和其用途 |
| US11958899B2 (en) | 2021-07-13 | 2024-04-16 | Mabwell Therapeutics Inc. | Anti-C1s antibodies and uses thereof |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| IL317947A (en) * | 2022-06-24 | 2025-02-01 | Bioverativ Usa Inc | Complementary disease treatment methods |
| AU2023385709A1 (en) | 2022-11-21 | 2025-06-12 | Dianthus Therapeutics Opco, Inc. | Antibodies that bind to c1s and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| DK2914291T3 (da) * | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2015084999A1 (en) * | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
-
2018
- 2018-03-14 CA CA3055781A patent/CA3055781A1/en active Pending
- 2018-03-14 SG SG11201907583TA patent/SG11201907583TA/en unknown
- 2018-03-14 WO PCT/US2018/022462 patent/WO2018170145A1/en not_active Ceased
- 2018-03-14 US US16/494,267 patent/US20210115116A1/en not_active Abandoned
- 2018-03-14 EP EP18715381.2A patent/EP3596121A1/en active Pending
- 2018-03-14 KR KR1020267006425A patent/KR20260039796A/ko active Pending
- 2018-03-14 CR CR20190468A patent/CR20190468A/es unknown
- 2018-03-14 MX MX2019010994A patent/MX2019010994A/es unknown
- 2018-03-14 JP JP2019550688A patent/JP7293122B2/ja active Active
- 2018-03-14 TW TW113122096A patent/TW202513092A/zh unknown
- 2018-03-14 BR BR112019018950-5A patent/BR112019018950A2/pt unknown
- 2018-03-14 CN CN201880029619.1A patent/CN110753701A/zh active Pending
- 2018-03-14 KR KR1020197029545A patent/KR102934707B1/ko active Active
- 2018-03-14 TW TW107108658A patent/TWI848905B/zh active
- 2018-03-14 AU AU2018236267A patent/AU2018236267B2/en active Active
- 2018-03-14 IL IL325084A patent/IL325084A/en unknown
-
2019
- 2019-09-08 IL IL269174A patent/IL269174B1/en unknown
- 2019-09-13 MX MX2025010483A patent/MX2025010483A/es unknown
-
2023
- 2023-03-01 JP JP2023030606A patent/JP2023071824A/ja active Pending
-
2025
- 2025-01-31 JP JP2025014511A patent/JP2025072437A/ja active Pending
- 2025-06-12 AU AU2025204392A patent/AU2025204392A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025072437A (ja) | 2025-05-09 |
| KR102934707B1 (ko) | 2026-03-06 |
| CA3055781A1 (en) | 2018-09-20 |
| CN110753701A (zh) | 2020-02-04 |
| KR20260039796A (ko) | 2026-03-20 |
| MX2025010483A (es) | 2025-10-01 |
| TWI848905B (zh) | 2024-07-21 |
| IL325084A (en) | 2026-02-01 |
| KR20190128676A (ko) | 2019-11-18 |
| EP3596121A1 (en) | 2020-01-22 |
| JP7293122B2 (ja) | 2023-06-19 |
| AU2018236267B2 (en) | 2025-03-13 |
| WO2018170145A1 (en) | 2018-09-20 |
| AU2025204392A1 (en) | 2025-07-03 |
| SG11201907583TA (en) | 2019-09-27 |
| TW202513092A (zh) | 2025-04-01 |
| AU2018236267A1 (en) | 2019-09-26 |
| JP2020511469A (ja) | 2020-04-16 |
| CR20190468A (es) | 2019-12-17 |
| TW201842931A (zh) | 2018-12-16 |
| MX2019010994A (es) | 2020-12-01 |
| IL269174B1 (en) | 2026-01-01 |
| US20210115116A1 (en) | 2021-04-22 |
| JP2023071824A (ja) | 2023-05-23 |
| IL269174A (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI848905B (zh) | 用於治療補體介導之疾病及病症之方法 | |
| US9732149B2 (en) | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement | |
| RU2709351C2 (ru) | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений | |
| AU2022215307B2 (en) | Methods of treating autoimmune and alloimmune disorders | |
| CN106132442B (zh) | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 | |
| US20100040537A1 (en) | Prostaglandin E2 Binding Proteins and Uses Thereof | |
| ES2731441T3 (es) | Anticuerpos dirigidos contra metaloproteinasa 9 de matriz | |
| JP7502865B2 (ja) | Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 | |
| CN109715209A (zh) | 用于治疗各种疾病和病症的抑制masp-3的组合物和方法 | |
| PT2097455E (pt) | Anticorpos anti-factor d humanizados | |
| ES2458665T9 (en) | Antibodies against tissue factor pathway inhibitor | |
| JP2019516395A (ja) | 第ｘｉ因子の活性部位に対するモノクローナル抗体及びその使用 | |
| EP3229829B1 (en) | Method for the treatment of idiopathic pulmonary fibrosis | |
| CN117241828A (zh) | 减少冷凝集素病患者的手术相关溶血 | |
| US20250145696A1 (en) | Methods for treating complement-mediated diseases and disorders | |
| HK40022920A (en) | Methods for treating complement-mediated diseases and disorders | |
| US20250136674A1 (en) | Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment | |
| WO2025094976A1 (ja) | ヘモジデリンの沈着及び／又は滑膜肥厚の改善又は抑制剤 | |
| BR112018069283B1 (pt) | Anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos | |
| BR112017020915B1 (pt) | Anticorpo caninizado isolado ou fragmento de ligação ao antígeno caninizado do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica e uso da mesma | |
| BR112017025693B1 (pt) | Anticorpo anti-cd40 antagonista de comprimento total e composição farmacêutica que compreende o referido anticorpo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25C | Requirement related to requested transfer of rights |
Owner name: BIOVERATIV USA INC. (US) Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870250030012 DE 14/04/2025, E NECESSARIO APRESENTAR A VALIDACAO DA ASSINATURA DO REPRESENTANTE DA EMPRESA CESSIONARIA COMO FOI FEITA COM A ASSINATURA DA CEDENTE OU APRESENTAR DOCUMENTO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
| B25A | Requested transfer of rights approved |
Owner name: RECORDATI UK LTD (GB) |